t
AstraZeneca PLC announced on 25 February 2026 that it filed its 2025 Annual Report on Form 20-F with the US Securities and Exchange Commission (SEC) on 24 February 2026. The document is available for viewing on the SEC and AstraZeneca websites. Holders of the Company's securities may request a hard copy of the complete audited financial statements free of charge.
| Date | 25 Feb 2026 |
| Time | 07:00:02 |
| Category | Results |
| ID | 0819U |
25 February 2026
Filing of Annual Report on Form 20-F with the US Securities and Exchange Commission
AstraZeneca PLC (the Company) announced today that, on 24 February 2026, it filed its 2025 Annual Report on Form 20-F with the US Securities and Exchange Commission (SEC). The document is available for viewing on the SEC website at www.sec.gov and also on the Company's website at www.astrazeneca.com. The Company will send any holder of the Company's securities, upon request, a hard copy of the Company's complete audited financial statements free of charge. Requests may be made by writing to the Company Secretary, AstraZeneca PLC, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA, UK.
AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Social Media @AstraZeneca.
Contacts
For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.
Matthew Bowden
Company Secretary
AstraZeneca PLC